Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 1/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.36 |
| ▸ | MTOR | P42345 | 2/20 | 0.33 |
| ▸ | RPTOR | Q8N122 | 1/20 | 0.32 |
| ▸ | MLST8 | Q9BVC4 | 1/20 | 0.32 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.32 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.32 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
| ▸ | CNR2 | P34972 | 1/20 | 0.30 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.30 |
| ▸ | SLC27A1 | Q6PCB7 | 1/20 | 0.30 |
| ▸ | POLB | P06746 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13933622 | 0.81 | HCAR2 (0.41) | KCNJ1MTORRPTORMLST8 | |
| SCHEMBL15603542 | 0.79 | GRIA1 (0.38) | GRIA1KCNJ1HRH3HCRTR1HCRTR2 | |
| SCHEMBL19121139 | 0.78 | MAPT (0.50) | GRIA1HCRTR1HCRTR2GPR119CNR1 | |
| SCHEMBL16827649 | 0.77 | P2RX7 (0.47) | GRIA1KCNJ1HRH3GPR119GRM1 | |
| SCHEMBL13954181 | 0.77 | KCNJ1 (0.36) | KCNJ1MTORRPTORMLST8 | |
| SCHEMBL16649082 | 0.77 | GRIA1 (0.38) | GRIA1KCNJ1HCRTR1HCRTR2CNR1 | |
| SCHEMBL17966634 | 0.77 | KDM4E (0.45) | KCNJ1GPR119CNR2 | |
| SCHEMBL28050493 | 0.76 | KMT2A (0.49) | MTORPOLB | |
| SCHEMBL16648881 | 0.76 | GRIA1 (0.36) | GRIA1HCRTR1HCRTR2GPR119 | |
| SCHEMBL16648883 | 0.76 | GRIA1 (0.36) | GRIA1HCRTR1HCRTR2GPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| EP-2862860-B1 | 1,3-OXAZOLIDINE OR 1,3-OXAZINANE COMPOUNDS AS OREXIN RECEPTOR ANTAGONISTS | TAISHO PHARMACEUTICAL CO LTD (JP) | 2016-12-21 | — | — | EP | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-9266870-B2 | Heteroaromatic methyl cyclic amine derivative | TAISHO PHARMACEUTICAL CO., LTD (JP) | 2016-02-23 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-07-02 | — | — | US | disclosed |
| US-20150166523-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2015-06-18 | — | — | US | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862860-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| EP-2862855-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2015-04-22 | — | — | EP | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | TAISHO PHARMACEUTICAL CO., LTD. (JP) | 2014-03-20 | — | — | US | disclosed |
| EP-2708537-A1 | HETEROAROMATIC RING DERIVATIVE | Taisho Pharmaceutical Co., Ltd. (JP) | 2014-03-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150166523-A1 | BRANCHED CHAIN ALKYL HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTR2B | GRIA1 38/4885KCNJ1 1127/4885MTOR 1166/4885 |
| US-20140081025-A1 | HETEROAROMATIC RING DERIVATIVE | HCRTR2, HCRTR1, HTT | GRIA1 59/4885KCNJ1 1043/4885MTOR 651/4885 |
| US-20150183768-A1 | HETEROAROMATIC METHYL CYCLIC AMINE DERIVATIVE | HCRTR2, HCRTR1, HTR2B | GRIA1 36/4885KCNJ1 2117/4885MTOR 548/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.